Midstage trial of Boehringer's anti-clot drug begins

12/10/2007 | Yahoo!

German drugmaker Boehringer Ingelheim GmbH on Sunday announced it has started a midstage trial to evaluate the safety and efficacy of its experimental drug dabigatran etexilate for patients with acute coronary syndrome. Dabigatran was found as effective as Sanofi-Aventis' Lovenox in preventing blood clots after hip surgery, and is expected to compete against Bayer's new drug rivaroxaban.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC